The Cooper Companies, Inc. (NASDAQ:COO – Get Free Report) shares reached a new 52-week low on Thursday after Needham & Company LLC lowered their price target on the stock from $86.00 to $73.00. Needham & Company LLC currently has a buy rating on the stock. Cooper Companies traded as low as $52.49 and last traded at $51.9960, with a volume of 249326 shares. The stock had previously closed at $63.48.
COO has been the subject of a number of other research reports. The Goldman Sachs Group set a $61.00 price target on shares of Cooper Companies in a research note on Wednesday, May 27th. Stifel Nicolaus reduced their target price on Cooper Companies from $95.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, June 5th. Citigroup reiterated a “neutral” rating and set a $80.00 price objective (up from $76.00) on shares of Cooper Companies in a research note on Thursday, August 13th. Mizuho set a $85.00 price objective on shares of Cooper Companies and gave the company an “outperform” rating in a research report on Thursday, June 4th. Finally, Piper Sandler cut shares of Cooper Companies from an “overweight” rating to a “neutral” rating and set a $59.00 price target on the stock. in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $74.93.
Get Our Latest Stock Report on COO
Cooper Companies News Roundup
- Positive Sentiment: COO reported fiscal Q3 adjusted EPS of $1.15, above the $1.11-$1.12 analyst consensus. GAAP EPS was $2.24, helped by a $307.2 million benefit from the favorable completion of a U.K. tax examination. Free cash flow increased 66% to $273 million. CooperCompanies Announces Third Quarter 2026 Results
- Positive Sentiment: The board expanded the share-repurchase authorization from $2 billion to $3 billion, potentially allowing repurchases of up to 22.7% of outstanding shares. Management also said it remains open to strategic alternatives that could create shareholder value. CooperCompanies Completes Strategic Review
- Neutral Sentiment: Third-quarter revenue rose roughly 1% year over year to $1.066 billion, with CooperVision revenue flat at $717 million and CooperSurgical revenue up 2% to $349.2 million. The results show continued profitability but limited underlying growth.
- Negative Sentiment: Revenue missed the approximately $1.10 billion consensus estimate, while fiscal 2026 adjusted EPS guidance was cut to $4.51-$4.55 from expectations near $4.63. Fourth-quarter EPS guidance of $1.05-$1.09 also trails the roughly $1.20 consensus. Analysts Lower Forecasts Following Q3 Results
- Negative Sentiment: CooperCompanies ended its strategic review by retaining CooperSurgical because potential offers were not attractive enough. Investors appear disappointed that the company will not receive sale proceeds, amid valuation pressure from a new non-hormonal IUD competitor and recent fertility-litigation costs.
- Negative Sentiment: Analysts responded by lowering price targets, including Needham to $73 from $86 and Bank of America to $65 from $80. Bank of America maintained a neutral rating, while the forecast reductions reinforced concerns about near-term growth.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in COO. California State Teachers Retirement System lifted its holdings in shares of Cooper Companies by 6,101.7% in the 2nd quarter. California State Teachers Retirement System now owns 19,460,014 shares of the medical device company’s stock valued at $1,395,478,000 after acquiring an additional 19,146,230 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of Cooper Companies during the second quarter valued at about $1,077,762,000. Generation Investment Management LLP purchased a new position in shares of Cooper Companies during the second quarter worth approximately $356,304,000. Wellington Management Group LLP lifted its stake in Cooper Companies by 332.9% in the 3rd quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock valued at $424,043,000 after buying an additional 4,756,178 shares in the last quarter. Finally, Jupiter Topco LLC purchased a new position in Cooper Companies during the second quarter worth approximately $305,074,000. 24.39% of the stock is owned by hedge funds and other institutional investors.
Cooper Companies Trading Down 17.4%
The company has a debt-to-equity ratio of 0.23, a current ratio of 1.27 and a quick ratio of 0.78. The business’s 50-day moving average price is $72.42 and its 200 day moving average price is $70.02. The firm has a market capitalization of $10.23 billion, a price-to-earnings ratio of 44.42, a PEG ratio of 1.77 and a beta of 0.82.
Cooper Companies (NASDAQ:COO – Get Free Report) last issued its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. The business had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.10 billion. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.The company’s quarterly revenue was up .5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, equities analysts forecast that The Cooper Companies, Inc. will post 4.63 earnings per share for the current fiscal year.
Cooper Companies announced that its board has authorized a share repurchase plan on Wednesday, September 9th that permits the company to buyback $3.00 billion in shares. This buyback authorization permits the medical device company to purchase up to 22.7% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its shares are undervalued.
Cooper Companies Company Profile
Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.
CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.
Read More
- Five stocks we like better than Cooper Companies
- Apple Unveils Foldable iPhone, But Stock’s Muted Reaction Raises Questions
- Palantir’s New U.S. Army Contract Brings It Closer to Owning the Full Battlefield System
- Life Time Keeps Beating Expectations, But Insiders Are Selling Into Strength
- Sezzle’s BNPL Growth Is Working, But the Stock Comes With a Catch
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.
